122 related articles for article (PubMed ID: 38554347)
61. Do ethnic chinese older adults with epithelial ovarian cancer survive a poorer prognosis?
Huang W; Bao Y; Luo X; Yao L; Yuan L
J Ovarian Res; 2023 Jun; 16(1):110. PubMed ID: 37277766
[TBL] [Abstract][Full Text] [Related]
62. CIAPIN1 nuclear accumulation predicts poor clinical outcome in epithelial ovarian cancer.
Cai X; Wang J; Xin X
World J Surg Oncol; 2012 Jun; 10():112. PubMed ID: 22713669
[TBL] [Abstract][Full Text] [Related]
63. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.
Son JH; Kong TW; Paek J; Song KH; Chang SJ; Ryu HS
Int J Gynaecol Obstet; 2017 Dec; 139(3):352-357. PubMed ID: 28857180
[TBL] [Abstract][Full Text] [Related]
64. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
[TBL] [Abstract][Full Text] [Related]
65. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
[TBL] [Abstract][Full Text] [Related]
66. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer.
Wang M; He Y; Shi L; Shi C
Eur J Gynaecol Oncol; 2011; 32(2):171-7. PubMed ID: 21614907
[TBL] [Abstract][Full Text] [Related]
67. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
Gynecol Oncol; 2018 Oct; 151(1):18-23. PubMed ID: 30135020
[TBL] [Abstract][Full Text] [Related]
68. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
Li Z; Yin H; Ren M; Shen Y
Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
[TBL] [Abstract][Full Text] [Related]
69. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.
Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB
Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932
[TBL] [Abstract][Full Text] [Related]
70. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
71. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer.
Thavaramara T; Phaloprakarn C; Tangjitgamol S; Manusirivithaya S
J Med Assoc Thai; 2011 Jul; 94(7):871-7. PubMed ID: 21774296
[TBL] [Abstract][Full Text] [Related]
72. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
73. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
74. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
Heitz F; Hengsbach A; Harter P; Traut A; Ataseven B; Schneider S; Prader S; Kurzeder C; Sporkmann M; du Bois A
Gynecol Oncol; 2017 Jan; 144(1):181-186. PubMed ID: 27863705
[TBL] [Abstract][Full Text] [Related]
75. Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
Ekmann-Gade AW; Høgdall CK; Seibæk L; Noer MC; Fagö-Olsen CL; Schnack TH
Gynecol Oncol; 2022 Jan; 164(1):120-128. PubMed ID: 34716025
[TBL] [Abstract][Full Text] [Related]
76. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
[TBL] [Abstract][Full Text] [Related]
77. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
78. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Hamilton CA; Miller A; Miller C; Krivak TC; Farley JH; Chernofsky MR; Stany MP; Rose GS; Markman M; Ozols RF; Armstrong DK; Maxwell GL
Gynecol Oncol; 2011 Sep; 122(3):521-6. PubMed ID: 21683993
[TBL] [Abstract][Full Text] [Related]
79. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
80. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
